BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

505 related articles for article (PubMed ID: 26253517)

  • 1. Sensitivity of Small Cell Lung Cancer to BET Inhibition Is Mediated by Regulation of ASCL1 Gene Expression.
    Lenhart R; Kirov S; Desilva H; Cao J; Lei M; Johnston K; Peterson R; Schweizer L; Purandare A; Ross-Macdonald P; Fairchild C; Wong T; Wee S
    Mol Cancer Ther; 2015 Oct; 14(10):2167-74. PubMed ID: 26253517
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MYCL is a target of a BET bromodomain inhibitor, JQ1, on growth suppression efficacy in small cell lung cancer cells.
    Kato F; Fiorentino FP; Alibés A; Perucho M; Sánchez-Céspedes M; Kohno T; Yokota J
    Oncotarget; 2016 Nov; 7(47):77378-77388. PubMed ID: 27764802
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ASXL3 bridges BRD4 to BAP1 complex and governs enhancer activity in small cell lung cancer.
    Szczepanski AP; Zhao Z; Sosnowski T; Goo YA; Bartom ET; Wang L
    Genome Med; 2020 Jul; 12(1):63. PubMed ID: 32669118
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sensitivity of human lung adenocarcinoma cell lines to targeted inhibition of BET epigenetic signaling proteins.
    Lockwood WW; Zejnullahu K; Bradner JE; Varmus H
    Proc Natl Acad Sci U S A; 2012 Nov; 109(47):19408-13. PubMed ID: 23129625
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting Myc in KSHV-associated primary effusion lymphoma with BET bromodomain inhibitors.
    Tolani B; Gopalakrishnan R; Punj V; Matta H; Chaudhary PM
    Oncogene; 2014 May; 33(22):2928-37. PubMed ID: 23792448
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BET bromodomain inhibition of MYC-amplified medulloblastoma.
    Bandopadhayay P; Bergthold G; Nguyen B; Schubert S; Gholamin S; Tang Y; Bolin S; Schumacher SE; Zeid R; Masoud S; Yu F; Vue N; Gibson WJ; Paolella BR; Mitra SS; Cheshier SH; Qi J; Liu KW; Wechsler-Reya R; Weiss WA; Swartling FJ; Kieran MW; Bradner JE; Beroukhim R; Cho YJ
    Clin Cancer Res; 2014 Feb; 20(4):912-25. PubMed ID: 24297863
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Compensatory RNA polymerase 2 loading determines the efficacy and transcriptional selectivity of JQ1 in Myc-driven tumors.
    Donato E; Croci O; Sabò A; Muller H; Morelli MJ; Pelizzola M; Campaner S
    Leukemia; 2017 Feb; 31(2):479-490. PubMed ID: 27443262
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting BRD4 proteins suppresses the growth of NSCLC through downregulation of eIF4E expression.
    Gao Z; Yuan T; Zhou X; Ni P; Sun G; Li P; Cheng Z; Wang X
    Cancer Biol Ther; 2018 May; 19(5):407-415. PubMed ID: 29333921
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of BET bromodomain-dependent XIAP and FLIP expression sensitizes KRAS-mutated NSCLC to pro-apoptotic agents.
    Klingbeil O; Lesche R; Gelato KA; Haendler B; Lejeune P
    Cell Death Dis; 2016 Sep; 7(9):e2365. PubMed ID: 27607580
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of Karyopherin β1-Mediated Nuclear Import Disrupts Oncogenic Lineage-Defining Transcription Factor Activity in Small Cell Lung Cancer.
    Kelenis DP; Rodarte KE; Kollipara RK; Pozo K; Choudhuri SP; Spainhower KB; Wait SJ; Stastny V; Oliver TG; Johnson JE
    Cancer Res; 2022 Sep; 82(17):3058-3073. PubMed ID: 35748745
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disruption of BRD4 at H3K27Ac-enriched enhancer region correlates with decreased c-Myc expression in Merkel cell carcinoma.
    Sengupta D; Kannan A; Kern M; Moreno MA; Vural E; Stack B; Suen JY; Tackett AJ; Gao L
    Epigenetics; 2015; 10(6):460-6. PubMed ID: 25941994
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transcriptional plasticity promotes primary and acquired resistance to BET inhibition.
    Rathert P; Roth M; Neumann T; Muerdter F; Roe JS; Muhar M; Deswal S; Cerny-Reiterer S; Peter B; Jude J; Hoffmann T; Boryń ŁM; Axelsson E; Schweifer N; Tontsch-Grunt U; Dow LE; Gianni D; Pearson M; Valent P; Stark A; Kraut N; Vakoc CR; Zuber J
    Nature; 2015 Sep; 525(7570):543-547. PubMed ID: 26367798
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Subtype-specific secretomic characterization of pulmonary neuroendocrine tumor cells.
    Wang XD; Hu R; Ding Q; Savage TK; Huffman KE; Williams N; Cobb MH; Minna JD; Johnson JE; Yu Y
    Nat Commun; 2019 Jul; 10(1):3201. PubMed ID: 31324758
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ascl1-induced Wnt11 regulates neuroendocrine differentiation, cell proliferation, and E-cadherin expression in small-cell lung cancer and Wnt11 regulates small-cell lung cancer biology.
    Tenjin Y; Kudoh S; Kubota S; Yamada T; Matsuo A; Sato Y; Ichimura T; Kohrogi H; Sashida G; Sakagami T; Ito T
    Lab Invest; 2019 Nov; 99(11):1622-1635. PubMed ID: 31231131
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of BET bromodomain inhibition in Kras-mutant non-small cell lung cancer.
    Shimamura T; Chen Z; Soucheray M; Carretero J; Kikuchi E; Tchaicha JH; Gao Y; Cheng KA; Cohoon TJ; Qi J; Akbay E; Kimmelman AC; Kung AL; Bradner JE; Wong KK
    Clin Cancer Res; 2013 Nov; 19(22):6183-92. PubMed ID: 24045185
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-tumor activity of BET inhibitors in androgen-receptor-expressing triple-negative breast cancer.
    Park IH; Yang HN; Jeon SY; Hwang JA; Kim MK; Kong SY; Shim SH; Lee KS
    Sci Rep; 2019 Sep; 9(1):13305. PubMed ID: 31527644
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Bromodomain Inhibitor JQ1 and the Histone Deacetylase Inhibitor Panobinostat Synergistically Reduce N-Myc Expression and Induce Anticancer Effects.
    Shahbazi J; Liu PY; Atmadibrata B; Bradner JE; Marshall GM; Lock RB; Liu T
    Clin Cancer Res; 2016 May; 22(10):2534-44. PubMed ID: 26733615
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative analysis of TTF-1 binding DNA regions in small-cell lung cancer and non-small-cell lung cancer.
    Hokari S; Tamura Y; Kaneda A; Katsura A; Morikawa M; Murai F; Ehata S; Tsutsumi S; Ishikawa Y; Aburatani H; Kikuchi T; Miyazono K; Koinuma D
    Mol Oncol; 2020 Feb; 14(2):277-293. PubMed ID: 31782890
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting bromodomain-containing protein 4 (BRD4) inhibits MYC expression in colorectal cancer cells.
    Otto C; Schmidt S; Kastner C; Denk S; Kettler J; Müller N; Germer CT; Wolf E; Gallant P; Wiegering A
    Neoplasia; 2019 Nov; 21(11):1110-1120. PubMed ID: 31734632
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BET bromodomain inhibitors suppress EWS-FLI1-dependent transcription and the IGF1 autocrine mechanism in Ewing sarcoma.
    Loganathan SN; Tang N; Fleming JT; Ma Y; Guo Y; Borinstein SC; Chiang C; Wang J
    Oncotarget; 2016 Jul; 7(28):43504-43517. PubMed ID: 27259270
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.